Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways plc (Nasdaq: CMPS) generates frequent news as it advances COMP360, its investigational synthetic psilocybin treatment, through late-stage clinical development for serious mental health conditions. The company focuses on treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and its updates often highlight progress in these programs, regulatory interactions, and collaborations related to potential delivery models.
News items for CMPS commonly cover clinical trial milestones, such as Phase 3 results in TRD and the design and initiation of late-stage trials in PTSD. For example, Compass has reported achievement of the primary endpoint in its COMP005 Phase 3 trial in TRD and the U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application for COMP360 in PTSD, enabling a Phase 2b/3 trial. Publications of clinical data in peer-reviewed journals, including results from a Phase 2 PTSD study, are also featured.
Investors and observers can also expect announcements about strategic collaborations with healthcare organizations and clinic networks. These collaborations, including those with Radial Health, Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, and HealthPort, are described as helping to inform how investigational COMP360 treatment might be integrated into various care settings if approved.
Additional CMPS news includes financial results, participation in investor and healthcare conferences, and corporate governance developments such as board appointments. Together, these updates provide context on Compass Pathways’ clinical, regulatory, and operational progress as it pursues evidence-based innovation in mental health. Readers interested in CMPS can use this news feed to follow key developments in the company’s COMP360 programs and broader mental health biotechnology strategy.
Compass Pathways (Nasdaq: CMPS) announced the FDA granted a rolling NDA submission and review for COMP360 and that COMP360 received a Commissioner's National Priority Voucher (CNPV) for treatment‑resistant depression (TRD).
The CNPV offers enhanced FDA communications and a shortened 1–2 month review window after NDA filing. Compass cites positive results from two Phase 3 trials across >1,000 TRD participants and reports rapid onset (as soon as one day) and durability through six months for responders, with most treatment‑emergent adverse events mild/moderate and resolving within 24 hours.
Compass Pathways (NASDAQ: CMPS) announced a collaboration with Osmind to study how small-to-medium independent psychiatry clinics can prepare to deliver psychedelic treatments, including COMP360, if FDA approved. The partnership will assess operational, clinical, and infrastructure needs across Osmind’s network of over 1,000 clinics to inform scalable, real-world delivery pathways.
Compass Pathways (Nasdaq: CMPS) announced CEO Kabir Nath will join a panel titled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026 from 11:00–12:00 ET.
A live audio webcast will stream from the company’s Investors > Events page, and a replay will be available for 30 days after the event.
Compass Pathways (Nasdaq: CMPS) welcomed the White House Executive Order to accelerate psychedelic treatments for serious mental illness. Compass highlighted two positive phase 3 COMP360 trials in treatment-resistant depression (TRD) with >1,000 participants, rapid effects within one day and durability to six months.
The company is working on a rolling FDA submission for COMP360 in TRD and is starting a late-stage PTSD trial after IND clearance.
Compass Pathways (Nasdaq: CMPS) launched a U.S. grant program to fund creation of provider training for investigational COMP360 psilocybin treatment ahead of a potential commercial launch. Compass expects to award up to three grants. Applications open April 14–May 14, 2026 at training-grants.compasspathways.com.
The program targets established U.S. training organizations to build foundational psychedelic and COMP360-specific modules to support clinical readiness and consistent patient care if COMP360 is approved.
Compass Pathways (Nasdaq: CMPS) will attend the Needham Virtual Healthcare Conference on April 14, 2026 and participate in a fireside chat at 12:45 PM ET. A live audio webcast will be available on the company’s Investors "Events" page.
According to the company, a replay of the webcast will be accessible for 30 days following the event.
Compass Pathways (Nasdaq: CMPS) granted inducement equity awards to seven newly hired non-executive employees on April 1, 2026 under the 2026 Inducement Plan.
The awards include options covering an aggregate of 117,445 shares and restricted share units or nominal cost options covering 55,875 shares, at an exercise price of $5.62, vesting over four years per grant terms.
Compass Pathways (Nasdaq: CMPS) reported Q4 and full-year 2025 results and business highlights on March 24, 2026. Key points: COMP360 achieved positive Phase 3 results showing rapid onset and durability in treatment resistant depression, FDA meeting planned for rolling NDA review, IND accepted for PTSD Phase 2b/3, and recent financings extend cash runway into 2028.
Financials: net loss $287.9M for FY2025, cash $149.6M at Dec 31, 2025, and debt $31.6M (reported), with additional $50.4M debt noted as of March 24, 2026.
Compass Pathways (Nasdaq: CMPS) management will attend the Stifel 2026 Virtual CNS Forum on March 17-18, 2026 and will take part in a fireside chat on March 18, 2026 at 10:30am ET.
A live audio webcast will be available on the company’s Investors > Events page, with a replay accessible for 30 days following the event.
Compass Pathways (Nasdaq: CMPS) exercised 35,059,448 outstanding warrants on February 26, 2026, generating approximately $200 million in proceeds. The company issued 15,160,619 ADSs and, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass intends to use these proceeds, plus ~$141 million from a Feb 20, 2026 public offering and existing cash, to fund COMP005 and COMP006 Phase 3 trials, a Phase 2b/3 COMP360 PTSD trial, commercial readiness, and working capital; combined funds are expected to fund operations into 2028.